Avadel Pharmaceuticals plc (AVDL) CEO Greg Divis on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/11/20
Implied Volatility Surging for Avadel Pharmaceuticals (AVDL) Stock OptionsZacks Investment Research • 04/08/20
Avadel Pharmaceuticals Completes the REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with NarcolepsyGlobeNewsWire • 03/25/20
Avadel Pharmaceuticals plc (AVDL) CEO Greg Divis on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/12/20
Avadel Pharmaceuticals Announces $65 Million Private Placement with Leading Biotech Investment FundsGlobeNewsWire • 02/21/20
Avadel Pharmaceuticals Completes Enrollment in the REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with NarcolepsyGlobeNewsWire • 12/17/19
Avadel Pharmaceuticals Receives U.S. FDA Approval for Nouress™ (AV001), a Cysteine Hydrochloride Injection for Treating Neonate Patients Requiring Total Parental Nutrition (TPN)GlobeNewsWire • 12/16/19
Avadel Pharmaceuticals Announces Key Appointments to Leadership Team To Support Continued Transformation and the Advancement of FT218GlobeNewsWire • 12/02/19